LOGIN  |  REGISTER
Amneal Pharmaceuticals
Astria Therapeutics

Emergent BioSolutions to Participate in Upcoming Investor Conferences

August 27, 2025 | Last Trade: US$8.30 0.09 -1.07

GAITHERSBURG, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences:

  • Wells Fargo 20th Annual Healthcare Conference
    September 4, 2025
    3:00 pm ET
    Webcast link here
    One-on-one meetings
  • HCW 27th Annual Global Investment Conference
    September 9, 2025
    1:30 PM ET
    Webcast link here
    One-on-one meetings

Please contact your conference representative to request one-on-one meetings.

Participants can view the presentations and replays by visiting the Investors page of Emergent’s website.

About Emergent BioSolutions

At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threat, visit our website and follow us on LinkedInXInstagramApple Podcasts and Spotify.

Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
This email address is being protected from spambots. You need JavaScript enabled to view it.  

Media Contact:
Assal Hellmer
Vice President, Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.

Astria Therapeutics

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page